Silvia Buonamici

USPTO Granted Patents = 10 (Patent Applications = 6)

CIPO Patents = 2 (Patent Applications = 2)

EPO Patents = 7 (Patent Applications = 9)

Average Co-Inventor Count = 8.1

ph-index = 1

Forward Citations = 3(Granted Patents)

Company Filing History:

9 out of 527

Eisai R&d Management Co., Ltd.

Years Active: 2015-2024

Loading Chart...

10 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12172986 - Splicing modulator antibody-drug conjugates and methods of use (2024-12-24),

2. 11998544 - Methods of using splicing modulators (2024-06-04),

3. 11945807 - Splicing modulator antibody-drug conjugates and methods of use (2024-04-02),

4. 11761045 - Splice variants associated with neomorphic SF3B1 mutants (2023-09-19),

5. 11524009 - Combination comprising at least one spliceosome modulator and at least one inhibitor chosen from BCL2 inhibitors, BCL2/BCLxL inhibitors, and BCLxL inhibitors and methods of use (2022-12-13),

6. 11352348 - Splicing modulator antibody-drug conjugates and methods of use (2022-06-07),

7. 10889866 - Splice variants associated with neomorphic SF3B1 mutants (2021-01-12),

8. 10745387 - Crystalline form of (2S,3S,6S,7R,10R,E)-7,10-dihydroxy-3,7-dimethyl-12-oxo-2-((R,2E,4E)-6-(piridin-2-yl)hepta-2,4-dien-2-yl)oxacyclododec-4-en-6-yl-4-methylpiperazine-1-carboxylate and methods of use thereof (2020-08-18),

9. 9481669 - Pladienolide pyridine compounds and methods of use (2016-11-01),

10. 9101559 - Leukemic cell CNS infiltration controlled by notch-induced chemotaxis (2015-08-11),

Title: The Innovative Contributions of Silvia Buonamici

Introduction

Silvia Buonamici is a prominent inventor based in Boston, MA, known for her significant contributions to the field of oncology. With a total of 10 patents to her name, she has made remarkable strides in developing novel therapeutic approaches for treating neoplastic disorders.

Latest Patents

Among her latest patents are groundbreaking inventions related to splicing modulator antibody-drug conjugates and methods of use. These patents disclose linker-drug compounds and antibody-drug conjugates that specifically bind to human oncology targets. The innovative linker-drug compounds and antibody-drug conjugates incorporate a splicing modulator drug moiety. Furthermore, her work includes methods and compositions for treating neoplastic disorders by administering the provided antibody-drug conjugates. In one embodiment, the splicing modulator comprises a pladienolide or a pladienolide derivative. Additionally, she has developed methods for treating neoplastic disorders by administering Compound 1, or a pharmaceutically acceptable salt thereof, either alone or as part of a conjugate or composition, which induces the production of at least one neoantigen.

Career Highlights

Silvia has worked with notable organizations such as Eisai R&D Management Co., Ltd. and New York University. Her experience in these institutions has allowed her to advance her research and contribute to the development of innovative therapies in oncology.

Collaborations

Throughout her career, Silvia has collaborated with esteemed colleagues, including Lihua Yu and Peter G. Smith. These partnerships have further enriched her research and expanded the impact of her inventions.

Conclusion

Silvia Buonamici's work exemplifies the spirit of innovation in the field of oncology. Her patents and collaborations highlight her dedication to advancing medical science and improving treatment options for patients with neoplastic disorders.

This text is generated by artificial intelligence and may not be accurate.